Short Interest in Cryo-Cell International, Inc. (NYSEAMERICAN:CCEL) Increases By 37.4%

Cryo-Cell International, Inc. (NYSEAMERICAN:CCEL) was the target of a significant increase in short interest in November. As of November 30th, there was short interest totalling 20,200 shares, an increase of 37.4% from the November 15th total of 14,700 shares. Currently, 0.6% of the company’s stock are short sold. Based on an average trading volume of 19,000 shares, the short-interest ratio is presently 1.1 days.

Cryo-Cell International Stock Up 0.4 %

Cryo-Cell International stock traded up $0.03 during trading on Friday, reaching $7.93. The stock had a trading volume of 3,636 shares, compared to its average volume of 11,126. Cryo-Cell International has a 52-week low of $4.47 and a 52-week high of $9.50. The company has a market capitalization of $63.92 million, a P/E ratio of -7.42 and a beta of 0.49.

Cryo-Cell International (NYSEAMERICAN:CCEL) last issued its quarterly earnings data on Tuesday, October 15th. The company reported $0.13 earnings per share for the quarter, topping the consensus estimate of $0.02 by $0.11. Cryo-Cell International had a negative net margin of 28.03% and a negative return on equity of 42.06%. The business had revenue of $8.07 million during the quarter.

Cryo-Cell International Announces Dividend

The firm also recently announced a — dividend, which was paid on Friday, November 29th. Stockholders of record on Friday, November 15th were paid a dividend of $0.25 per share. The ex-dividend date was Friday, November 15th. Cryo-Cell International’s dividend payout ratio (DPR) is -94.34%.

Institutional Trading of Cryo-Cell International

An institutional investor recently raised its position in Cryo-Cell International stock. Geode Capital Management LLC increased its position in shares of Cryo-Cell International, Inc. (NYSEAMERICAN:CCEL) by 68.5% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 39,860 shares of the company’s stock after purchasing an additional 16,203 shares during the period. Geode Capital Management LLC owned approximately 0.49% of Cryo-Cell International worth $254,000 as of its most recent SEC filing. 10.44% of the stock is owned by hedge funds and other institutional investors.

About Cryo-Cell International

Cryo-Cell International, Inc engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, auto-immune diseases, multiple sclerosis, Alzheimer's disease, Parkinson's diseases.